Hormone replacement therapy: An analysis of efficacy based on evidence

Geriatrics

Volumn 57, Issue 8, 2002, Pages 18-24

  Gupta, Gayatri ^a   Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; RALOXIFENE;

AGING; CLINICAL TRIAL; COGNITION; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HEART PROTECTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INCONTINENCE; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSE; NEUROPROTECTION; OSTEOPOROSIS; REVIEW; VAGINA DISEASE; VALIDATION PROCESS;

CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; RISK ASSESSMENT; URINARY INCONTINENCE;

EID: 0036669809     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130(7):545-53.
2. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991; 325(11):756-62.
3. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996; 276(17):1397-403.
4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7):605-13.
5. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288(1):49-57.
6. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288(1):58-66.
7. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343(8):522-9.
8. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3):321-333.
9. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287(7):847-57.
10. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001; 88(4):392-5.
11. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990; 97(12):1080-6.
12. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med 1993 153(1):73-9.
13. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345(17):1243-9.
14. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T. Postmenopausal hormones and incontinence: The Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97(1):116-20.
15. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276(17):1389-96.
16. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; 2(8205):1151-4.
17. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann intern Med 1992; 117(1):1-9.
18. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction, Osteoporos Int 1998; 8(suppl 4):S7-80.
19. Smith CA, McCleary CA, Murdock GA, et al. Lifelong estrogen exposure and cognitive performance in elderly women. Brain Cogn 1999; 39(3):203-18.
20. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: Systematic review and meta-analysis. JAMA 2001; 285(11):1489-99.
21. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283(8):1007-15.
22. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002; 287(5):591-7.
23. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275(5):370-5.
24. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350(9084):1047-59.